10,838 Shares of CVS Health Corporation $CVS Bought by Victory Financial Group LLC

Victory Financial Group LLC bought a new position in shares of CVS Health Corporation (NYSE:CVS) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 10,838 shares of the pharmacy operator’s stock, valued at approximately $929,000.

Other institutional investors have also modified their holdings of the company. BlackRock Inc. acquired a new stake in CVS Health during the 2nd quarter valued at approximately $12,747,462,000. State Street Corp raised its position in shares of CVS Health by 26.3% in the 2nd quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator’s stock valued at $7,751,205,000 after purchasing an additional 15,604,883 shares in the last quarter. Wellington Management Group LLP raised its position in shares of CVS Health by 49.8% in the 2nd quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator’s stock valued at $3,496,725,000 after purchasing an additional 11,233,381 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of CVS Health by 148.0% during the 2nd quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator’s stock valued at $2,398,868,000 after buying an additional 13,836,701 shares during the last quarter. Finally, Pzena Investment Management LLC purchased a new position in shares of CVS Health during the 2nd quarter valued at approximately $1,217,558,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: A bullish preview upgraded CVS to “buy” with a $115 price target, citing accelerating earnings, higher guidance, improved margins, lower leverage, strong free cash flow and a sustainable dividend. CVS previously reported quarterly revenue growth of 7.3% and EPS well above consensus. CVS Q3 Preview: Accelerating Growth, Near 3% Yield, Meaningful Upside Long-Term
• Positive Sentiment: CVS is reportedly piloting a program that expands pharmacists’ role in chronic-care management. If successful, the initiative could improve patient engagement, support care outcomes and create additional healthcare-service revenue opportunities. CVS Health is reportedly piloting pharmacists in chronic health management
• Neutral Sentiment: Analysts’ average recommendation remains equivalent to “buy,” but the reports caution that consensus ratings can be overly optimistic and should not be viewed as a standalone investment signal. Brokers Suggest Investing in CVS Health
• Negative Sentiment: CVS and its Aetna unit sued to challenge Medicare Advantage star ratings that could reduce payments by approximately $2 billion. The litigation highlights potentially material pressure on the company’s government-benefits business and creates uncertainty around future earnings. CVS sues to prevent $2B Medicare Advantage star ratings hit
• Negative Sentiment: The University of Kentucky sued CVS, alleging RICO violations and claiming the university is owed $41 million. The case adds another legal overhang and could raise costs or reputational concerns if the allegations gain traction. UK sues CVS, accuses the pharmacy of RICO
• Negative Sentiment: Pharmacy workers in Rhode Island rallied over staffing and contract issues, signaling continued labor and operating challenges across CVS’s retail footprint. CVS workers in Rhode Island rally over staffing

CVS Health Trading Down 1.2%

NYSE:CVS opened at $89.99 on Thursday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74. The business’s 50 day moving average is $91.36 and its two-hundred day moving average is $88.67. CVS Health Corporation has a 52 week low of $69.51 and a 52 week high of $110.68. The company has a market cap of $115.10 billion, a PE ratio of 23.81, a P/E/G ratio of 0.87 and a beta of 0.60.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping the consensus estimate of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%. The company had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. During the same quarter last year, the firm earned $1.81 EPS. The business’s revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, analysts predict that CVS Health Corporation will post 8.02 EPS for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Thursday, October 22nd will be paid a dividend of $0.6650 per share. The ex-dividend date is Thursday, October 22nd. This represents a $2.66 annualized dividend and a yield of 3.0%. CVS Health’s payout ratio is presently 70.37%.

Analyst Ratings Changes

A number of analysts have recently weighed in on CVS shares. BMO Capital Markets set a $112.00 price target on shares of CVS Health in a research report on Wednesday, September 9th. Weiss Ratings cut shares of CVS Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, October 9th. Argus increased their price objective on shares of CVS Health from $104.00 to $114.00 and gave the company a “buy” rating in a research note on Wednesday, August 19th. Leerink Partners decreased their price objective on shares of CVS Health from $119.00 to $112.00 and set an “outperform” rating for the company in a report on Monday, October 12th. Finally, Wells Fargo & Company raised their price objective on shares of CVS Health from $103.00 to $123.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Twenty equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $107.80.

CVS Health Company Profile

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.